176 related articles for article (PubMed ID: 18952417)
1. Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors.
Scarpelli R; Di Marco A; Ferrigno F; Laufer R; Marcucci I; Muraglia E; Ontoria JM; Rowley M; Serafini S; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6078-82. PubMed ID: 18952417
[TBL] [Abstract][Full Text] [Related]
2. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
[TBL] [Abstract][Full Text] [Related]
3. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
[TBL] [Abstract][Full Text] [Related]
5. Amino acid derivatives as histone deacetylase inhibitors.
Hubbs JL; Zhou H; Kral AM; Fleming JC; Dahlberg WK; Hughes BL; Middleton RE; Szewczak AA; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Jan; 18(1):34-8. PubMed ID: 18042381
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
7. Benzo[b]thiophene-based histone deacetylase inhibitors.
Witter DJ; Belvedere S; Chen L; Secrist JP; Mosley RT; Miller TA
Bioorg Med Chem Lett; 2007 Aug; 17(16):4562-7. PubMed ID: 17576064
[TBL] [Abstract][Full Text] [Related]
8. 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers.
Nikolakopoulos G; Figler H; Linden J; Scammells PJ
Bioorg Med Chem; 2006 Apr; 14(7):2358-65. PubMed ID: 16314104
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
10. 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies.
Ragno R; Mai A; Massa S; Cerbara I; Valente S; Bottoni P; Scatena R; Jesacher F; Loidl P; Brosch G
J Med Chem; 2004 Mar; 47(6):1351-9. PubMed ID: 14998325
[TBL] [Abstract][Full Text] [Related]
11. N-(thiazol-2-yl)-2-thiophene carboxamide derivatives as Abl inhibitors identified by a pharmacophore-based database screening of commercially available compounds.
Manetti F; Falchi F; Crespan E; Schenone S; Maga G; Botta M
Bioorg Med Chem Lett; 2008 Aug; 18(15):4328-31. PubMed ID: 18621522
[TBL] [Abstract][Full Text] [Related]
12. A series of novel, potent, and selective histone deacetylase inhibitors.
Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
[TBL] [Abstract][Full Text] [Related]
13. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides.
Mai A; Massa S; Pezzi R; Simeoni S; Rotili D; Nebbioso A; Scognamiglio A; Altucci L; Loidl P; Brosch G
J Med Chem; 2005 May; 48(9):3344-53. PubMed ID: 15857140
[TBL] [Abstract][Full Text] [Related]
14. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
Andrianov V; Gailite V; Lola D; Loza E; Semenikhina V; Kalvinsh I; Finn P; Petersen KD; Ritchie JW; Khan N; Tumber A; Collins LS; Vadlamudi SM; Björkling F; Sehested M
Eur J Med Chem; 2009 Mar; 44(3):1067-85. PubMed ID: 18672316
[TBL] [Abstract][Full Text] [Related]
15. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.
Mahboobi S; Dove S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2009 Apr; 52(8):2265-79. PubMed ID: 19301902
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase.
Marson CM; Mahadevan T; Dines J; Sengmany S; Morrell JM; Alao JP; Joel SP; Vigushin DM; Charles Coombes R
Bioorg Med Chem Lett; 2007 Jan; 17(1):136-41. PubMed ID: 17046252
[TBL] [Abstract][Full Text] [Related]
17. Benzo[b]thiophene-2-carboxamides and benzo[b]furan-2-carboxamides are potent antagonists of the human H3-receptor.
Peschke B; Bak S; Hohlweg R; Nielsen R; Viuff D; Rimvall K
Bioorg Med Chem Lett; 2006 Jun; 16(12):3162-5. PubMed ID: 16616493
[TBL] [Abstract][Full Text] [Related]
18. Design of novel histone deacetylase inhibitors.
Siliphaivanh P; Harrington P; Witter DJ; Otte K; Tempest P; Kattar S; Kral AM; Fleming JC; Deshmukh SV; Harsch A; Secrist PJ; Miller TA
Bioorg Med Chem Lett; 2007 Aug; 17(16):4619-24. PubMed ID: 17555962
[TBL] [Abstract][Full Text] [Related]
19. Structural origin of selectivity in class II-selective histone deacetylase inhibitors.
Estiu G; Greenberg E; Harrison CB; Kwiatkowski NP; Mazitschek R; Bradner JE; Wiest O
J Med Chem; 2008 May; 51(10):2898-906. PubMed ID: 18412327
[TBL] [Abstract][Full Text] [Related]
20. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
